Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hospitalized for acute heart failure~* Dyspnea at rest or with minimal exertion~* Pulmonary congestion~* Able to provide informed consent~* Systolic blood pressure \> 125 mmHg~* Impaired renal function defined as an eGFR of 30-75 mL/min/1.73m2~Exclusion Criteria:~* Use of other IV therapies for acute heart failure~* Fever or sepsis~* Recent major neurologic event~* Recent major surgery~* Recent acute coronary syndrome~* Other recent investigational drug use

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): 48 hour iv infusion of placebo
- Relaxin (Type: EXPERIMENTAL): 48 hour iv infusion of relaxin at 30 ug/kg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).